RIMEGEPANT
Information current as at: 1 April 2025
PBAC meeting date: March 2024
Submission Details
- Brand name:
-
- Nurtec® ODT
- Pharmaceutical company:
- Pfizer Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Acute migrane attacks
- PBAC Submission type:
- New listing (Early Re-entry Pathway)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2024
- Related medicines:
Progress Details
-
Submission received for: - March 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 22/11/2023 and close 31/01/2024 (see PBS Website)
-
PBAC meeting: - Held on 13/03/2024
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a865
Page last updated: 02 April 2025